These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36118183)

  • 1. Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials.
    Debasu Z; Kedir HM; Tadesse TA
    Int J Gen Med; 2022; 15():7201-7208. PubMed ID: 36118183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Coleman CI; Kharat AA; Bookhart B; Baker WL
    Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis.
    Chen C; Kan Y; Shi Z; Guo D; Fu W; Li Y; Lv Q; Li X; Si Y
    Front Pharmacol; 2020; 11():608247. PubMed ID: 33732144
    [No Abstract]   [Full Text] [Related]  

  • 4. Do we have a unified consensus on antithrombotic management of PAD?
    Poredos P; Antignani PL; Blinc A; Fras Z; Jezovnik MK; Fareed J; Mansilha A
    Int Angiol; 2021 Jun; 40(3):229-239. PubMed ID: 33739074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials.
    Zhu H; Xu X; Wang H; Chen Q; Fang X; Zheng J; Gao B; Tong G; Zhou L; Chen T; Huang J
    Front Cardiovasc Med; 2022; 9():1040473. PubMed ID: 36698936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy with or without anticoagulant therapy for lower extremity peripheral artery disease: A systematic review.
    Rahmatian D; Barry AR
    Am J Health Syst Pharm; 2021 Nov; 78(23):2132-2141. PubMed ID: 34059879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
    Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
    Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States.
    Hernandez L; Shah A; Zhao Q; Milentijevic D; Kharat A
    Am Health Drug Benefits; 2020; 13(5):184-190. PubMed ID: 33343818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.
    Scott LJ
    Drugs; 2020 Sep; 80(14):1465-1475. PubMed ID: 32910441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
    Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
    Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials.
    Costa G; Gonçalves L; Teixeira R
    J Thromb Thrombolysis; 2021 Oct; 52(3):904-913. PubMed ID: 33704652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
    Lee MC; Liao CT; Toh HS; Chou CC; Chang WT; Chen ZC; Wu WS; Yu T; Strong C
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):539-547. PubMed ID: 32910340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis.
    Sibbing D; Blaha MJ; Chawla R; Lavalle-Cobo A; Kishore A; Lanas A; Li L; Santilli F; Schnell O; Shi Z
    Eur Cardiol; 2024; 19():e01. PubMed ID: 38708371
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.